Murine antibodies that block cell-surface antigens have been engineered (humanized) to successfully elicit human immune-effector mechanisms. Now, a fully human antibody produced entirely in vitro kills tumor cells directly through signal transduction and shows promise against lymphoma in animal studies (pages 801–807).
This is a preview of subscription content, log in via an institution to check access.
References
Nagy, Z.A. et al. Fully human, HLA-DR-specific monoclonal antibodies efficient induce programmed death of malignant lymphoid cells. Nature Med. 8, 801–807 (2002).
Nadler, L.M. et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40, 3147–3154 (1980).
Scott, D.W. et al. Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-mu of WEHI-231 and the selection and properties of resistant mutants. Cell Immunol. 93, 124–131 (1985).
Vuist, W.M. et al. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83, 899–906 (1994).
Ashwell, J.D., Longo, D.L. & Bridges, S.H. T-cell tumor elimination as a result of T-cell-receptor-mediated activation. Science 237, 61–64 (1987).
Funakoshi, S. et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83, 2787–2794 (1994).
Tian, Z.G. et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. 55, 5335–5341 (1995).
Alas, S. & Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 61, 5137–5144 (2001).
Bridges, S.H., Kruisbeek, A.M. & Longo, D.L. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B-cell lymphoma. J. Immunol. 139, 4242–4249 (1987).
Knappik, A. et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296, 57–86 (2000).
Brown, K.S., Levitt, D.J., Shannon, M. & Link, B.K. Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. Clin. Lymphoma 2, 188–190 (2001).
Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937–1947 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Longo, D. DR's orders: Human antibody kills tumors by direct signaling. Nat Med 8, 781–783 (2002). https://doi.org/10.1038/nm0802-781
Issue Date:
DOI: https://doi.org/10.1038/nm0802-781
- Springer Nature America, Inc.
This article is cited by
-
Soluble CD4 effectively prevents excessive TLR activation of resident macrophages in the onset of sepsis
Signal Transduction and Targeted Therapy (2023)